Simplex Trading
BTAI icon

Simplex Trading’s BioXcel Therapeutics BTAI Stock Holding History

Simplex Trading’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-163
Closed -$4K – 8578
2024
Q4 		$4K Sell
163
-125
-43% -$1.04K ﹤0.01% 7708
2024
Q3 		$2K Sell
288
-3,056
-91% -$41.1K ﹤0.01% 7958
2024
Q2 		$68K Buy
3,344
+863
+35% +$28.9K ﹤0.01% 5759
2024
Q1 		$111K Buy
2,481
+1,987
+402% +$94.8K ﹤0.01% 5472
2023
Q4 		$23K Buy
494
+181
+58% +$10.1K ﹤0.01% 6796
2023
Q3 		$12K Sell
313
-2,275
-88% -$230K ﹤0.01% 7028
2023
Q2 		$275K Buy
2,588
+1,575
+155% +$524K ﹤0.01% 3947
2023
Q1 		$302K Buy
1,013
+994
+5,232% +$424K ﹤0.01% 3831
2022
Q4 		$6K Buy
19
+6
+46% +$1.45K ﹤0.01% 7909
2022
Q3 		$2K Hold
13
– – ﹤0.01% 9239
2022
Q2 		$2K Hold
13
– – ﹤0.01% 9299
2022
Q1 		$4K Sell
13
-56
-81% -$16.2K ﹤0.01% 9519
2021
Q4 		$22K Sell
69
-94
-58% -$40.3K ﹤0.01% 8246
2021
Q3 		$74K Hold
163
– – ﹤0.01% 7029
2021
Q2 		$75K Buy
163
+159
+3,975% +$86.7K ﹤0.01% 7128
2021
Q1 		$306K Buy
+4
New +$3.22K ﹤0.01% 4119
2020
Q3 		– Sell
-4
Closed -$296K – 7801
2020
Q2 		$296K Sell
4
-29
-88% -$18.9K ﹤0.01% 3544
2020
Q1 		$1.16M Buy
+33
New +$11.9K ﹤0.01% 1737

Other funds holding BTAI

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Simplex Trading's BTAI Position: Q4 2024 in Review

Simplex Trading sold out of BioXcel Therapeutics (BTAI) in Q4 2024, closing a stake of 195 shares — an estimated $1.63K sold.

Simplex Trading first reported a position in BTAI in Q1 2020 and held it in 14 quarters. The position peaked at $1.66M in Q2 2020. 49 funds tracked by Wall St. Rank hold BTAI as of Q4 2024.

  • Simplex Trading reported no remaining BioXcel Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Simplex Trading sold 195 BioXcel Therapeutics shares in Q4 2024, an estimated $1.63K.
  • Simplex Trading first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 14 quarters.
  • Simplex Trading's BioXcel Therapeutics position peaked at $1.66M in Q2 2020.
  • 49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2024.

Based on Simplex Trading's 13F filing for Q4 2024, filed 11 Feb 2025.